<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classes of drugs and chemicals associated with skin and mucous membrane hyperpigmentation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classes of drugs and chemicals associated with skin and mucous membrane hyperpigmentation</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classes of drugs and chemicals associated with skin and mucous membrane hyperpigmentation</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="20%"></colgroup><colgroup width="60%"></colgroup> <tbody> <tr> <td class="subtitle1">Class</td> <td class="subtitle1">Drug or chemical</td> <td class="subtitle1">Clinical features</td> </tr> <tr> <td class="divider_bottom" rowspan="6">Chemotherapeutic agents</td> <td>Bleomycin</td> <td> <ul> <li>Linear, flagellate bands </li> <li>Hyperpigmentation over joints, striae, and/or palmar creases </li> </ul> </td> </tr> <tr> <td>Busulfan, cyclophosphamide, procarbazine</td> <td> <ul> <li>Diffuse hyperpigmentation of the skin and mucous membranes </li> <li>Pigment localized to the nails, palms/soles, or teeth </li> </ul> </td> </tr> <tr> <td>Cisplatin, docetaxel, doxorubicin, idarubicin</td> <td> <ul> <li>Hyperpigmentation overlying the small joints of the hands and involving the palmar creases, palms/soles, and oral mucosa including the tongue </li> </ul> </td> </tr> <tr> <td>Fluorouracil</td> <td> <ul> <li>Hyperpigmentation in sun-exposed areas </li> <li>Pigmentation along veins used for infusions* </li> </ul> </td> </tr> <tr> <td>Hydroxyurea</td> <td> <ul> <li>Hyperpigmentation over pressure points and on the back </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Methotrexate</td> <td> <ul> <li>Hyperpigmentation in sun-exposed areas and hair </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Antimalarials</td> <td>Aminoquinolines</td> <td> <ul> <li>Gray-blue pigmentation on pretibial surfaces and also the face, hard palate, sclerae, and subungual areas </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Hormones</td> <td>Oral contraceptives</td> <td> <ul> <li>Hyperpigmentation of the nipples </li> <li>Increased pigmentation of nevi </li> <li>Hyperpigmented patches of the face (melasma) </li> </ul> </td> </tr> <tr> <td class="divider_bottom" rowspan="6">Heavy metals</td> <td>Arsenic</td> <td> <ul> <li>Areas of bronze hyperpigmentation </li> </ul> </td> </tr> <tr> <td>Gold (chrysiasis)</td> <td> <ul> <li>Permanent blue-gray pigmentation in sun-exposed areas, especially periorbital </li> </ul> </td> </tr> <tr> <td>Iron</td> <td> <ul> <li>Permanent brown pigment at injection or application sites </li> </ul> </td> </tr> <tr> <td>Lead</td> <td> <ul> <li>Pigmentation at gingival margin </li> </ul> </td> </tr> <tr> <td>Mercury</td> <td> <ul> <li>Slate-gray discoloration, especially in skin folds </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Silver (argyria)</td> <td> <ul> <li>Generalized slate-gray discoloration, increased in sun-exposed areas, nails, sclerae, oral mucosa, or application sites </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="divider_bottom">Prostaglandin agonists</td> <td>Bimatoprost, latanoprost, tafluprost, travoprost, unoprostone</td> <td> <ul> <li>Increased brown pigmentation of iris, eyelids, eyelashes, and periorbital skin </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="divider_bottom">Smoking</td> <td>Nicotine and other substances in tobacco smoke</td> <td> <ul> <li>Brown hyperpigmented lesions of oral mucosa, lips, and gingiva (smoker's melanosis) </li> </ul> </td> </tr> <tr> <td rowspan="9">Miscellaneous</td> <td>Amiodarone</td> <td> <ul> <li>Slate-gray discoloration in sun-exposed areas, especially face </li> </ul> </td> </tr> <tr> <td>Clofazimine</td> <td> <ul> <li>Diffuse red-brown discoloration of the skin </li> <li>Blue-brown to violaceous discoloration in lesional skin </li> </ul> </td> </tr> <tr> <td>Diltiazem</td> <td> <ul> <li>Slate-gray-brown pigmentation of sun-exposed areas, especially in darker skin types, may have perifollicular accentuation and reticulated pattern </li> </ul> </td> </tr> <tr> <td>Ezogabine</td> <td> <ul> <li>Blue-gray discoloration of skin, nails, conjunctivae, and oral mucosa </li> </ul> </td> </tr> <tr> <td>Minocycline<sup>Â¶</sup></td> <td> <ul> <li>Generalized "muddy" brown discoloration </li> <li>Blue-black discoloration in old acne scars or sites of inflammation as well as lower extremities </li> <li>Pigmentation may also involve the nails, sclerae, oral mucosa, bones, thyroid, and teeth </li> </ul> </td> </tr> <tr> <td>Psoralens</td> <td> <ul> <li>Increased skin pigmentation after exposure to ultraviolet A light </li> </ul> </td> </tr> <tr> <td>Psychotropic drugs (amitriptyline, chlorpromazine, desipramine, imipramine, thioridazine)</td> <td> <ul> <li>Slate-gray pigmentation in sun-exposed areas </li> </ul> </td> </tr> <tr> <td>Tacrolimus, topical</td> <td> <ul> <li>Brown pigmented macules at application sites </li> </ul> </td> </tr> <tr> <td>Zidovudine</td> <td> <ul> <li>Mucocutaneous hyperpigmentation that can be widespread/diffuse, acral, or on oral mucosa </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">Drug and chemical exposures associated with skin hyperpigmentation. Drug-associated skin hyperpigmentation generally affects sun-exposed areas and may also involve mucous membranes. Clinical features vary; pigmentation often fades slowly and incompletely following withdrawal of the offending agent.</div><div class="graphic_footnotes">* Pigmentation along veins for infusion is also associated with vinorelbine, cisplatin, docetaxel, and other chemotherapeutic infusions.<br/>Â¶ Skin discoloration is described less frequently with use of tetracyclines other than minocycline; this may be due to more frequent prolonged courses of treatment and higher cumulative doses in use of minocycline (eg, in acne treatment) relative to the other tetracyclines.</div><div class="graphic_reference">Adapted from: Kang S, Lerner EA, Sober AJ, Levine N. Pigmentary disorders from exogenous causes. In: Pigmentation and Pigmentary Disorders, Levine N (Ed), CRC Press, 1993. Updated with data from Krause W. Drug-induced hyperpigmentation: A systematic review; J Dtsch Dermatol Ges 2013; 11:644.</div><div id="graphicVersion">Graphic 94552 Version 8.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
